Autolus Therapeutics plc is a clinical-stage biopharmaceutical company that develops T cell therapies to treat cancer. They have several clinical-stage programs, including obecabtagene autoleucel (AUTO1), AUTO4, and AUTO8, which are in various stages of clinical trials for the treatment of different types of cancer. The company also focuses on developing AUTO5, a hematological product candidate, in preclinical development.